JP2024069192A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024069192A5 JP2024069192A5 JP2024015822A JP2024015822A JP2024069192A5 JP 2024069192 A5 JP2024069192 A5 JP 2024069192A5 JP 2024015822 A JP2024015822 A JP 2024015822A JP 2024015822 A JP2024015822 A JP 2024015822A JP 2024069192 A5 JP2024069192 A5 JP 2024069192A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- subject
- administration
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000011252 Phenylketonuria Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- VPVOXUSPXFPWBN-UHFFFAOYSA-N L-sepiapterin Natural products N1=C(N)NC(=O)C2=C1NCC(C(=O)C(O)C)=N2 VPVOXUSPXFPWBN-UHFFFAOYSA-N 0.000 claims 3
- VPVOXUSPXFPWBN-VKHMYHEASA-N sepiapterin Chemical compound N1C(N)=NC(=O)C2=C1NCC(C(=O)[C@@H](O)C)=N2 VPVOXUSPXFPWBN-VKHMYHEASA-N 0.000 claims 3
- 229940126478 sepiapterin Drugs 0.000 claims 3
- 210000004556 brain Anatomy 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862677943P | 2018-05-30 | 2018-05-30 | |
| US62/677,943 | 2018-05-30 | ||
| US201862771398P | 2018-11-26 | 2018-11-26 | |
| US62/771,398 | 2018-11-26 | ||
| US201962822376P | 2019-03-22 | 2019-03-22 | |
| US62/822,376 | 2019-03-22 | ||
| GC201937663 | 2019-05-28 | ||
| GC2019-37663 | 2019-05-28 | ||
| PCT/US2019/034523 WO2019232130A1 (en) | 2018-05-30 | 2019-05-30 | Methods for increasing sepiapterin plasma exposure |
| JP2020566655A JP7502197B2 (ja) | 2018-05-30 | 2019-05-30 | セピアプテリン血漿曝露を増加させるための方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566655A Division JP7502197B2 (ja) | 2018-05-30 | 2019-05-30 | セピアプテリン血漿曝露を増加させるための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024069192A JP2024069192A (ja) | 2024-05-21 |
| JP2024069192A5 true JP2024069192A5 (enExample) | 2024-08-22 |
Family
ID=68699037
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566655A Active JP7502197B2 (ja) | 2018-05-30 | 2019-05-30 | セピアプテリン血漿曝露を増加させるための方法 |
| JP2024015822A Pending JP2024069192A (ja) | 2018-05-30 | 2024-02-05 | セピアプテリン血漿曝露を増加させるための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566655A Active JP7502197B2 (ja) | 2018-05-30 | 2019-05-30 | セピアプテリン血漿曝露を増加させるための方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11617752B2 (enExample) |
| EP (2) | EP3801536B1 (enExample) |
| JP (2) | JP7502197B2 (enExample) |
| CN (1) | CN112703002A (enExample) |
| AU (2) | AU2019277382B2 (enExample) |
| CA (1) | CA3102106A1 (enExample) |
| DK (1) | DK3801536T3 (enExample) |
| ES (1) | ES2986920T3 (enExample) |
| FI (1) | FI3801536T3 (enExample) |
| HR (1) | HRP20241213T1 (enExample) |
| HU (1) | HUE068589T2 (enExample) |
| LT (1) | LT3801536T (enExample) |
| MD (1) | MD3801536T2 (enExample) |
| MX (2) | MX2020012979A (enExample) |
| PL (1) | PL3801536T3 (enExample) |
| PT (1) | PT3801536T (enExample) |
| RS (1) | RS65874B1 (enExample) |
| SI (1) | SI3801536T1 (enExample) |
| SM (1) | SMT202400430T1 (enExample) |
| WO (1) | WO2019232130A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ753504A (en) | 2016-11-29 | 2025-10-31 | Ptc Therapeutics Mp Inc | Polymorphs of sepiapterin and salts thereof |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| CN111491635A (zh) | 2017-09-01 | 2020-08-04 | 显莎制药公司 | 包含墨蝶呤的药物组合物及其用途 |
| JP7547215B2 (ja) | 2018-05-30 | 2024-09-09 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法 |
| US11617752B2 (en) | 2018-05-30 | 2023-04-04 | Ptc Therapeutics Mp, Inc. | Methods for increasing sepiapterin plasma exposure |
| WO2021150983A1 (en) * | 2020-01-24 | 2021-07-29 | Ptc Therapeutics Mp, Inc. | Methods for treating parkinson's disease with sepiapterin |
| US20230077104A1 (en) * | 2020-02-19 | 2023-03-09 | The United States Government As Represented By The Department Of Veteran Affairs | L-sepiapterin and methods of use for treating diseases and disorders |
| US20240122931A1 (en) * | 2021-02-09 | 2024-04-18 | Ptc Therapeutics Mp, Inc. | Methods for treating covid-19 with sepiapterin |
| AU2022221345A1 (en) * | 2021-02-09 | 2023-09-07 | Ptc Therapeutics Mp, Inc. | Methods for treating glioblastomas with sepiapterin |
| CN120732846A (zh) * | 2025-04-09 | 2025-10-03 | 中南大学湘雅医院 | 吲哚乙酸在制备预防或治疗高血压产品中的用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| US5910304A (en) | 1982-12-13 | 1999-06-08 | Texas A&M University System | Low-dose oral administration of interferons |
| CA1320905C (en) | 1986-11-06 | 1993-08-03 | Joseph M. Cummins | Treatment of immuno-resistant disease |
| US5736343A (en) | 1995-08-18 | 1998-04-07 | Landry; Donald | Detection of organic compounds through regulation of antibody-catalyzed reactions |
| US6036949A (en) | 1998-03-05 | 2000-03-14 | Amarillo Biosciences, Inc. | Treatment of fibromyalgia with low doses of interferon |
| US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| JP2007511520A (ja) | 2003-11-13 | 2007-05-10 | ザ ジェネラル ホスピタル コーポレーション | 疼痛を治療するための方法 |
| US7732599B2 (en) | 2003-11-17 | 2010-06-08 | Biomarin Pharmaceutical Inc. | Process for preparing tetrahydrobiopterin and analogs of tetrahydrobiopterin |
| CN1894251B (zh) | 2003-11-17 | 2011-06-29 | 默克和西伊公司 | (6r)-l-赤型-四氢生物蝶呤二盐酸盐的晶型 |
| PL1708690T3 (pl) | 2003-11-17 | 2017-01-31 | Biomarin Pharmaceutical Inc. | Leczenie fenyloketonurii za pomocą BH4 |
| CN101132776A (zh) | 2004-11-17 | 2008-02-27 | 生物马林药物股份有限公司 | 稳定的四氢生物喋呤片剂制剂 |
| JP2008523090A (ja) | 2004-12-08 | 2008-07-03 | バイオマリン ファーマシューティカル インコーポレイテッド | 新生児肺高血圧症の治療のための方法および組成物 |
| BRPI0609421B1 (pt) | 2005-04-28 | 2021-06-01 | Shiratori Pharmaceutical Co., Ltd. | Processos para produção de um composto 1,1-bis-alquil sulfonila, para produção de um composto aldeído, e para produção de um derivado de hidrazona |
| US20080075666A1 (en) | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
| ES2906582T3 (es) * | 2007-04-11 | 2022-04-19 | Biomarin Pharm Inc | Métodos para administrar tetrahidrobiopterina, composiciones asociadas y métodos de medida |
| US20110144117A1 (en) | 2008-08-12 | 2011-06-16 | Orpha Swiss Gmbh | Pharmaceutical Dosage Form Containing Tetrahydrobiopterin |
| WO2011132435A1 (ja) * | 2010-04-22 | 2011-10-27 | 学校法人日本大学 | 脳機能障害予防・改善用の薬剤及び飲食物 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| CN103458900A (zh) | 2011-03-01 | 2013-12-18 | 鲁必康研究私人有限公司 | 四氢生物蝶呤的稳定组合物 |
| US9216178B2 (en) * | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| ES2681345T3 (es) | 2012-05-07 | 2018-09-12 | Shiratori Pharmaceutical Co., Ltd. | Método para producir sepiapterina y tetrahidrolactoilpterina |
| EP3213062B1 (en) * | 2014-10-31 | 2020-02-12 | Children's Medical Center Corporation | Methods and assays relating to sepiapterin reductase inhibition |
| MA46972A (fr) | 2016-11-29 | 2019-10-09 | Censa Pharmaceuticals Inc | Forme polymorphe de sépiaptérine |
| NZ753504A (en) | 2016-11-29 | 2025-10-31 | Ptc Therapeutics Mp Inc | Polymorphs of sepiapterin and salts thereof |
| CN111491635A (zh) | 2017-09-01 | 2020-08-04 | 显莎制药公司 | 包含墨蝶呤的药物组合物及其用途 |
| US11335708B2 (en) * | 2017-11-23 | 2022-05-17 | Semiconductor Energy Laboratory Co., Ltd. | Display device having a plurality of thin film transistors per pixel |
| EP3807279B1 (en) | 2018-05-30 | 2025-12-31 | PTC Therapeutics MP, Inc. | Pharmaceutically acceptable sepiapterin salts with improved stability |
| JP7547215B2 (ja) | 2018-05-30 | 2024-09-09 | ピーティーシー セラピューティクス エムピー，インコーポレイテッド | テトラヒドロビオプテリン血漿曝露を増加させるための組成物及び方法 |
| US11617752B2 (en) | 2018-05-30 | 2023-04-04 | Ptc Therapeutics Mp, Inc. | Methods for increasing sepiapterin plasma exposure |
| DK4009978T3 (da) | 2019-08-05 | 2024-10-14 | Ptc Therapeutics Mp Inc | Anvendelse af Sepiapterin og metabolitter deraf for at behandle strålingseksponering |
| ES3041002T3 (en) | 2019-09-25 | 2025-11-06 | Ptc Therapeutics Mp Inc | Methods for treating hyperphenylalaninemia |
-
2019
- 2019-05-30 US US17/059,719 patent/US11617752B2/en active Active
- 2019-05-30 MX MX2020012979A patent/MX2020012979A/es unknown
- 2019-05-30 SM SM20240430T patent/SMT202400430T1/it unknown
- 2019-05-30 MD MDE20210340T patent/MD3801536T2/ro unknown
- 2019-05-30 CA CA3102106A patent/CA3102106A1/en active Pending
- 2019-05-30 EP EP19811888.7A patent/EP3801536B1/en active Active
- 2019-05-30 HU HUE19811888A patent/HUE068589T2/hu unknown
- 2019-05-30 DK DK19811888.7T patent/DK3801536T3/da active
- 2019-05-30 SI SI201930841T patent/SI3801536T1/sl unknown
- 2019-05-30 HR HRP20241213TT patent/HRP20241213T1/hr unknown
- 2019-05-30 AU AU2019277382A patent/AU2019277382B2/en active Active
- 2019-05-30 PL PL19811888.7T patent/PL3801536T3/pl unknown
- 2019-05-30 FI FIEP19811888.7T patent/FI3801536T3/fi active
- 2019-05-30 ES ES19811888T patent/ES2986920T3/es active Active
- 2019-05-30 RS RS20240943A patent/RS65874B1/sr unknown
- 2019-05-30 CN CN201980050839.7A patent/CN112703002A/zh active Pending
- 2019-05-30 EP EP24187175.5A patent/EP4454704A3/en active Pending
- 2019-05-30 JP JP2020566655A patent/JP7502197B2/ja active Active
- 2019-05-30 LT LTEPPCT/US2019/034523T patent/LT3801536T/lt unknown
- 2019-05-30 PT PT198118887T patent/PT3801536T/pt unknown
- 2019-05-30 WO PCT/US2019/034523 patent/WO2019232130A1/en not_active Ceased
-
2020
- 2020-11-30 MX MX2024005935A patent/MX2024005935A/es unknown
-
2023
- 2023-03-31 US US18/129,177 patent/US12329757B2/en active Active
-
2024
- 2024-02-05 JP JP2024015822A patent/JP2024069192A/ja active Pending
-
2025
- 2025-02-06 AU AU2025200814A patent/AU2025200814A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024069192A5 (enExample) | ||
| EP3426240B1 (en) | Mixed salt compositions for producing elevated and sustained ketosis | |
| JP2024074963A5 (enExample) | ||
| JPS61277618A (ja) | 自閉症治療剤 | |
| JP2018507243A5 (enExample) | ||
| FI3801536T3 (fi) | Sepiapteriinin antaminen ilman ruokaa käytettäväksi menetelmässä sepiapteriinin plasma-altistuksen lisäämiseksi | |
| CN103298464A (zh) | 复方组合物 | |
| JPS62111924A (ja) | 恐慌障害の軽減剤 | |
| FI4034122T3 (fi) | Menetelmiä hyperfenyylialaninemian hoitamiseksi | |
| JP2024019691A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| US20060233892A1 (en) | Topiramate compositions for treatment of headache | |
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2001518481A (ja) | 経口投与のためのセロトニン含有製剤及びその使用方法 | |
| JPWO2019232130A5 (enExample) | ||
| RU2709500C1 (ru) | Фармацевтическая композиция для парентерального капельного введения | |
| WO2017101696A1 (zh) | 治疗急慢性呼吸困难的西药组合物及其制备方法 | |
| CN109172550B (zh) | 一种复合麻醉药物 | |
| Bardsley | Chronic respiratory failure in COPD: is there a place for a respiratory stimulant? | |
| JPWO2019232126A5 (enExample) | ||
| JPWO2022026767A5 (enExample) | ||
| RU2412701C2 (ru) | Способ снижения непереносимости противотуберкулезных препаратов | |
| JP2003159028A (ja) | 花粉症治療用食品 | |
| JPH0415766B2 (enExample) | ||
| EP0372676A1 (en) | Therapeutic preparation and method | |
| JP2004532866A (ja) | ２型インスリン抵抗性真性糖尿病患者の治療のためのビオチンと組合せてのアセチルｌ−カルニチンの使用 |